No Photo Available

Last Update

2016-04-23T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Irma Grossi?

Dr. Irma M. Grossi

Senior Director, Preclinical Pharmaceutical Sciences

RTI International

Direct Phone: (919) ***-****       

Email: g***@***.org

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

RTI International

3040 Cornwallis Road

Research Triangle Park, North Carolina 27709

United States

Company Description

RTI International, the nation's second largest independent nonprofit research organization, is dedicated to conducting research and development that improves the human condition by turning knowledge into practice. RTI has more than 2,500 staff members who ... more

Find other employees at this company (5,146)

Background Information

Employment History

The Ohio State University

Affiliations

Member
Society of Toxicology

Education

PhD

Web References (39 Total References)


Health Economics & Solutions - Pharmacoepidemiology & Outcomes Research - RTI International

www.rti.org [cached]

Health Sciences Welcomes Irma Grossi as Senior Director of Life Sciences and Toxicology -12.12.2005


Scientific Leadership - RTI Health Solutions

www.rtihs.com [cached]

Irma Grossi, PhD Senior Director, Preclinical Pharmaceutical Sciences

...
Dr. Irma M. Grossi is Senior Director of Preclinical Pharmaceutical Sciences at RTI-HS, where she is responsible for managing professional and support staff in the planning and implementation of preclinical development programs for new lead candidates. She develops project plans and budgets and monitors technical and financial performance of LST projects, establishing and monitoring corrective action when required. Dr. Grossi has 12 years of experience in preclinical drug development toward investigational new drug (IND) application filings with responsibilities in Good Laboratory Practices (GLP) toxicology ranging from appointments as Study Director/Senior Study Director/Team Leader (IRDC/MPI Research and Battelle Memorial Institute), Laboratory Director (Liberty Research), and Program Manager/Toxicology Manager (Battelle Memorial Institute) to establishing and operating a GLP Toxicology Department for an animal health production and supply company (Liberty Research). Her experience includes conducting, supervising, and coordinating of individual acute, repeat dose, subchronic and chronic toxicology studies for the commercial industry and for the National Cancer Institute (NCI). Dr. Grossi has managed various preclinical toxicology programs and staff who provide drug development support for IND and new drug application (NDA) submissions to the US Food and Drug Administration (FDA), as well as support for the US Environmental Protection Agency (EPA) and European registrations for industrial and government clients. She has extensive experience with leading multidisciplinary teams in performing various programs for NCI, biotechnologies, and multinational pharmaceutical companies. Dr. Grossi has served as the Principal Investigator (PI) on multiyear contracts for anti-AIDS therapies and antineoplastic drugs for the NCI Toxicology and Pharmacology Branch, the Developmental Therapeutics Program, and the Division of Cancer Treatment and Diagnosis. She was the focal point of all program communications and was responsible for the technical and fiscal components for studies associated with each contract. Her work in toxicology and pharmacokinetics has appeared in many publications, including numerous peer-reviewed journal articles and abstracts, and she has authored or coauthored eight book chapters.
Email Irma Grossi


Scientific Leadership - RTI Health Solutions

www.rtihs.com [cached]

Irma Grossi, PhD Senior Director, Preclinical Pharmaceutical Sciences

...
Dr. Irma M. Grossi is Senior Director of Preclinical Pharmaceutical Sciences at RTI-HS, where she is responsible for managing professional and support staff in the planning and implementation of preclinical development programs for new lead candidates. She develops project plans and budgets and monitors technical and financial performance of LST projects, establishing and monitoring corrective action when required. Dr. Grossi has 12 years of experience in preclinical drug development toward investigational new drug (IND) application filings with responsibilities in Good Laboratory Practices (GLP) toxicology ranging from appointments as Study Director/Senior Study Director/Team Leader (IRDC/MPI Research and Battelle Memorial Institute), Laboratory Director (Liberty Research), and Program Manager/Toxicology Manager (Battelle Memorial Institute) to establishing and operating a GLP Toxicology Department for an animal health production and supply company (Liberty Research). Her experience includes conducting, supervising, and coordinating of individual acute, repeat dose, subchronic and chronic toxicology studies for the commercial industry and for the National Cancer Institute (NCI). Dr. Grossi has managed various preclinical toxicology programs and staff who provide drug development support for IND and new drug application (NDA) submissions to the US Food and Drug Administration (FDA), as well as support for the US Environmental Protection Agency (EPA) and European registrations for industrial and government clients. She has extensive experience with leading multidisciplinary teams in performing various programs for NCI, biotechnologies, and multinational pharmaceutical companies. Dr. Grossi has served as the Principal Investigator (PI) on multiyear contracts for anti-AIDS therapies and antineoplastic drugs for the NCI Toxicology and Pharmacology Branch, the Developmental Therapeutics Program, and the Division of Cancer Treatment and Diagnosis. She was the focal point of all program communications and was responsible for the technical and fiscal components for studies associated with each contract. Her work in toxicology and pharmacokinetics has appeared in many publications, including numerous peer-reviewed journal articles and abstracts, and she has authored or coauthored eight book chapters.
Email Irma Grossi


Scientific Leadership - RTI Health Solutions

www.rtihs.com [cached]

Irma Grossi, PhD Senior Director, Preclinical Pharmaceutical Sciences

...
Dr. Irma M. Grossi is Senior Director of Preclinical Pharmaceutical Sciences at RTI-HS, where she is responsible for managing professional and support staff in the planning and implementation of preclinical development programs for new lead candidates. She develops project plans and budgets and monitors technical and financial performance of LST projects, establishing and monitoring corrective action when required. Dr. Grossi has 12 years of experience in preclinical drug development toward investigational new drug (IND) application filings with responsibilities in Good Laboratory Practices (GLP) toxicology ranging from appointments as Study Director/Senior Study Director/Team Leader (IRDC/MPI Research and Battelle Memorial Institute), Laboratory Director (Liberty Research), and Program Manager/Toxicology Manager (Battelle Memorial Institute) to establishing and operating a GLP Toxicology Department for an animal health production and supply company (Liberty Research). Her experience includes conducting, supervising, and coordinating of individual acute, repeat dose, subchronic and chronic toxicology studies for the commercial industry and for the National Cancer Institute (NCI). Dr. Grossi has managed various preclinical toxicology programs and staff who provide drug development support for IND and new drug application (NDA) submissions to the US Food and Drug Administration (FDA), as well as support for the US Environmental Protection Agency (EPA) and European registrations for industrial and government clients. She has extensive experience with leading multidisciplinary teams in performing various programs for NCI, biotechnologies, and multinational pharmaceutical companies. Dr. Grossi has served as the Principal Investigator (PI) on multiyear contracts for anti-AIDS therapies and antineoplastic drugs for the NCI Toxicology and Pharmacology Branch, the Developmental Therapeutics Program, and the Division of Cancer Treatment and Diagnosis. She was the focal point of all program communications and was responsible for the technical and fiscal components for studies associated with each contract. Her work in toxicology and pharmacokinetics has appeared in many publications, including numerous peer-reviewed journal articles and abstracts, and she has authored or coauthored eight book chapters.
Email Irma Grossi


Preclinical Pharmaceutical Sciences - RTI Health Solutions

www.rtihs.com [cached]

Irma Grossi, PhD Senior Director, Preclinical Pharmaceutical Sciences

...
ยป Irma Grossi

Similar Profiles

Other People with this Name

Other people with the name Grossi

Troy Grossi
D&GG LLC

Wayne Grossi

Mauricio Grossi
Mygo Consulting Inc

Adam Grossi
Devry Smith Frank LLP

Carolyn Grossi
Magna International Inc

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory